EUCTR2021-003717-18-GR进行中（未招募）1 期
An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab in pediatric participants with mild to moderate COVID-19 at high risk of disease progression - COMET-PACE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Participant must be 32 weeks estimated gestational age (EGA), day of life (DOL) 0 to <18 years of age inclusive, at either the time of participant’s signed assent (if age-appropriate) or parent(s)/legally authorized representative signing the informed consent.
- •Type of Participant and Disease Characteristics
- •2. Participants with mild-moderate COVID-19, as defined by:
- •A positive SARS-CoV-2 test result by any validated qRT-PCR or other nucleic acid amplification test (NAAT) AND
- •SpO2 =94% on room air AND
- •Have one or more of the following symptoms: fever, chills, cough, sore throat, malaise, headache, joint or muscle pain, change in smell or taste, vomiting, diarrhea, shortness of breath, poor appetite or poor feeding, nasal congestion/runny nose, lethargy AND
- •Less than or equal to 7 days from onset of symptoms to dosing day (Day 1).
- •3. Participants at risk of disease progression with at least one of the following criteria:
- •Age <1 year
- •Diabetes mellitus
- •Genetic or metabolic diseases
- •Obesity (as defined as body mass index (kg/m2) =95th percentile for age and sex based on local growth charts for children =2 years of age)
- •Cardiovascular disease
- •Sickle cell disease
- •Pulmonary disease
- •Neurologic disease
- •Immunosuppressed (due to certain medical conditions or being on medications that weaken the immune system
- •o Use of systemic corticosteroids is included as defined by dose =0.5 mg/kg/day or 20 mg/day prednisone equivalents (whichever dose is the lower of the two) taken for =2 weeks
- •Baseline medical complexity (gastrostomy- or jejunostomy-dependence, parenteral nutrition dependence, tracheostomy-dependence, baseline oxygen requirement, use of CPAP/BiPAP/ventilator support).
- •4. Body weight with the range stated below:
- •Preterm newborn infants and term newborn infants: =2 kg
- •Children 2 years to <18 years:
- •o Body mass index (BMI) =5th percentile for age based on local growth charts.
- •Sex and Contraceptive/Barrier Requirements
- •5. Male and/or female
- •Contraception and barriers as well as pregnancy testing is required for females only, as appropriate for the age and sexual activity of pediatric participants and as required by local regulations regarding the methods of contraception for those participating in clinical studies.
- •A female participant is eligible to participate if she is not breastfeeding and is either:
- •Premenarcheal or
- •Not pregnant as confirmed by a negative pregnancy test (serum or highly sensitive urine as required by local regulations) at Screening, before the first dose of study intervention, if of reproductive potential.
- •o If a urine test cannot be confirmed as negative, a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
- •o See protocol for additional requirements for pregnancy testing during the study participation.
- •Women of childbearing potential (WOCBP) must commit to using a contraceptive method that is highly effective, with a failure rate of <1%, during the study intervention period and for at least 36 weeks after the last dose of study intervention. The investigator should evaluate potential for contraceptive method failure in relationship to the first dose of study intervention.
- •The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a female with an early undetected pregnancy.
- •6. The inve
排除标准
- •Medical Conditions
- •1. Pregnant or breastfeeding.
- •2. Currently hospitalized, or judged by the investigator as likely to require hospitalization in the next 24 hours, due to severe or critical COVID-19.
- •Note: If the infant has been hospitalized due to other reasons (e.g., prematurity) or will be hospitalized for reason of administering the study treatment then they can be included in the study.
- •3. Respiratory rate:
- •0-6 months: >60 breaths/minute (min)
- •6 months to 5 years: >30 breaths/min
- •6 years to <18 years: >20 breaths/min
- •4. Shortness of breath at rest or respiratory distress.
- •5. Shock (septic, neurogenic, anaphylactic, cardiogenic, or hypovolemic shock; systemic inflammatory response syndrome).
- •6. Multiorgan dysfunction.
- •7. Participants who, in the judgement of the investigator are likely to die in the next 7 days.
- •8. Multisystem inflammatory syndrome in children (MIS-C) [CDC HAN, 2020], defined as a participant:
- •a. Participants presenting with fever =38°C, laboratory evidence of inflammation (such as elevated C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid, lactate dehydrogenase [LDH], interleukin 6 [IL-6], neutrophilia, lymphopenia or hypoalbuminemia) and evidence of clinically severe illness requiring hospitalization, with multisystem (=2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological);
- •b. No alternative plausible diagnoses;
- •c. Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.
- •9. Post-conceptional age less than 32 completed weeks at time of Screening.
- •10. History of sudden infant death or unexplained death in a sibling.
- •11. For Cohort B only: Participant has any condition that would prohibit receipt of IM injections in the investigator’s opinion such as coagulation disorder, bleeding diathesis, or thrombocytopenia (platelet count <50,000/mm3).
- •Prior/Concomitant Therapy
- •12. Prior, current, or planned future use of any of the following treatments during the study period: COVID-19 convalescent plasma, mAbs against SARS-CoV-2 (e.g., casirivimab/imdevimab), intravenous immunoglobulin (IVIG) for any indication, or dexamethasone specifically for treatment of COVID-19.
- •13. Current use of COVID-19 treatment (authorized, approved, or investigational).
- •14. The following exclusions related to use of an authorized or approved vaccine for SARS-CoV-2 are applicable:
- •a) Receipt of any authorized or approved vaccine for SARS-CoV-2 within 48 hours prior to dosing.
- •b) Planned use of any authorized or approved vaccine for SARS-CoV-2 within 90 days of study drug administration per current CDC recommendations.
- •15. Receipt of any non-SARS-CoV-2 vaccines within 14 days (for non-live vaccines) or 28 days (for live vaccine) of Screening.
- •Prior/Concurrent Clinical Study Experience
- •16. Has participated, or is participating, in a clinical research study evaluating COVID-19 convalescent plasma, mAbs against SARS-CoV-2 (e.g. casirivimab/imdevimab) or IVIG within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the Screening visit.
- •17. Has participated, is participating, or plans to participate during the study period in a clinical research study evaluation of any authorized, approved or investigational vaccine for SARS
研究者
相似试验
进行中（未招募）
不适用
Triptorelin 6-month formulation for children who mature too early because of a brain hormoneEUCTR2015-001607-30-Outside-EU/EEADebiopharm International, S.A.44
进行中（未招募）
1 期
An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis. - BATT (Bicalutamide anastrozole treatment for testotoxicosis)testotoxicosis (familial male-limited gonadotropin-independent precocious puberty)MedDRA version: 7.1 Level: PT Classification code 10063654EUCTR2004-000384-10-GBAstraZeneca AB14
进行中（未招募）
不适用
An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis. - BATT (Biclutamide anatrozole treatment for testotoxicosis)testotoxicosis (familial male-limited gonadotropin-independent precocious puberty)MedDRA version: 7.1Level: PTClassification code 10063654EUCTR2004-000384-10-FRAstraZeneca AB20
进行中（未招募）
1 期
Evaluation of a new paediatric formulation of hydroxycarbamide in children with sickle cell diseaseEUCTR2022-000168-22-FRAddmedica45
进行中（未招募）
不适用
The objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty including growth in height, and development of muscles and sexual organs.testotoxicosis (precocious puberty)MedDRA version: 14.1Level: PTClassification code 10063654Term: TestotoxicosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-001180-77-Outside-EU/EEAAstraZeneca14